168 related articles for article (PubMed ID: 34258514)
1. The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells.
van Gils N; Martiañez Canales T; Vermue E; Rutten A; Denkers F; van der Deure T; Ossenkoppele GJ; Giles F; Smit L
Hemasphere; 2021 Aug; 5(8):e610. PubMed ID: 34258514
[TBL] [Abstract][Full Text] [Related]
2. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma.
Ryan KR; Giles F; Morgan GJ
Eur J Haematol; 2021 Jan; 106(1):90-99. PubMed ID: 32997383
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.
Spriano F; Gaudio E; Cascione L; Tarantelli C; Melle F; Motta G; Priebe V; Rinaldi A; Golino G; Mensah AA; Aresu L; Zucca E; Pileri S; Witcher M; Brown B; Wahlestedt C; Giles F; Stathis A; Bertoni F
Blood Adv; 2020 Sep; 4(17):4124-4135. PubMed ID: 32882003
[TBL] [Abstract][Full Text] [Related]
4. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death.
Kuang C; Tong J; Ermine K; Cai M; Dai F; Hao S; Giles F; Huang Y; Yu J; Zhang L
Front Oncol; 2022; 12():1018775. PubMed ID: 36313707
[TBL] [Abstract][Full Text] [Related]
6. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
[TBL] [Abstract][Full Text] [Related]
7. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
[TBL] [Abstract][Full Text] [Related]
8. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
[No Abstract] [Full Text] [Related]
9. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.
Giotopoulos G; Chan WI; Horton SJ; Ruau D; Gallipoli P; Fowler A; Crawley C; Papaemmanuil E; Campbell PJ; Göttgens B; Van Deursen JM; Cole PA; Huntly BJ
Oncogene; 2016 Jan; 35(3):279-89. PubMed ID: 25893291
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
Strachowska M; Robaszkiewicz A
Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
[TBL] [Abstract][Full Text] [Related]
11. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
[TBL] [Abstract][Full Text] [Related]
12. Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients.
Dennison JL; Al-Ali H; Volmar CH; Brothers S; Watts J; Wahlestedt C; Lohse I
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077629
[TBL] [Abstract][Full Text] [Related]
13. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
14. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
15. Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
Xiang Q; Wu T; Zhang C; Wang C; Xu H; Hu Q; Hu J; Luo G; Zhuang X; Wu X; Zhang Y; Xu Y
Bioorg Chem; 2024 Jan; 142():106950. PubMed ID: 37924753
[TBL] [Abstract][Full Text] [Related]
16. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia.
Magliulo D; Bernardi R; Messina S
Front Oncol; 2018; 8():255. PubMed ID: 30073149
[TBL] [Abstract][Full Text] [Related]
17. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.
Zucconi BE; Luef B; Xu W; Henry RA; Nodelman IM; Bowman GD; Andrews AJ; Cole PA
Biochemistry; 2016 Jul; 55(27):3727-34. PubMed ID: 27332697
[TBL] [Abstract][Full Text] [Related]
18. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).
Braun T; Gardin C
Expert Opin Investig Drugs; 2017 Jul; 26(7):803-811. PubMed ID: 28541716
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
Kim TK; Gore SD; Zeidan AM
Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]